Literature DB >> 34199041

Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil.

Adriana Samide1, Bogdan Tutunaru1, Renata-Maria Varut2, Bogdan Oprea3, Simona Iordache1,4.   

Abstract

In order to anticipate the effect induced by a natural product on the chemical activity of medicines simultaneously administered, spontaneous interactions of certain cancer treatment drugs such as, epirubicin (EPR), gemcitabine (GCT), and paclitaxel (PTX) with limonene (LIM)-a natural compound extracted from orange peel and known as an anticancer agent-were investigated. To estimate the stability of the drugs over time, a current density of 50 mA cm-2 was applied as an external stimulus between two platinum electrodes immersed in hydrochloric acid solution containing ethyl alcohol/water in the volume ratio of 2/3, in the absence and presence of orange essential oil (limonene concentration of 95%). The concentration variation of chemotherapeutic agents over time was evaluated by UV-Vis spectrophotometry. Kinetic studies have shown a delay in the decomposition reaction of epirubicin and gemcitabine and a paclitaxel activity stimulation. Thus, in the presence of limonene, the epirubicin half-life increased from 46.2 min to 63 min, and from 6.2 min to 8.6 min in gemcitabine case, while for paclitaxel a decrease of half-life from 35.9 min to 25.8 min was determined. Therefore, certain drug-limonene interactions took place, leading to the emergence of molecular micro-assemblies impacting decomposition reaction of chemotherapeutics. To predict drug-limonene interactions, the Autodock 4.2.6 system was employed. Thus, two hydrophobic interactions and five π-alkyl interactions were established between EPR-LIM, the GCT-LIM connection involves four π-alkyl interactions, and the PTX-LIM bridges take place through three hydrophobic interactions and the one π-alkyl. Finally, the decomposition reaction mechanism of drugs was proposed.

Entities:  

Keywords:  Autodock 4.2.6 system; chemotherapeutics; experimental and kinetic studies; interactions; limonene; quantum chemical calculation

Year:  2021        PMID: 34199041     DOI: 10.3390/ph14070619

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  36 in total

1.  R-Limonene metabolism in humans and metabolite kinetics after oral administration.

Authors:  Lukas Schmidt; Thomas Göen
Journal:  Arch Toxicol       Date:  2016-06-21       Impact factor: 5.153

2.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

3.  Effect of aromatherapy on cancer complications: A systematic review.

Authors:  Mansoureh Ashghali Farahani; Roghaiyeh Afsargharehbagh; Fatemeh Marandi; Mojgan Moradi; Seyed-Mehdi Hashemi; Mahdieh Poodineh Moghadam; Abbas Balouchi
Journal:  Complement Ther Med       Date:  2019-08-05       Impact factor: 2.446

4.  Effect of some volatile oils on the affinity of intact and oxidized low-density lipoproteins for adrenal cell surface receptors.

Authors:  Gholam Ali Naderi; Seddigheh Asgary; Mohsen Ani; Nizal Sarraf-Zadegan; Mohammad Reza Safari
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

5.  Limonene: electronic state spectroscopy by high-resolution vacuum ultraviolet photoabsorption, electron scattering, He(I) photoelectron spectroscopy and ab initio calculations.

Authors:  M A Śmiałek; M-J Hubin-Franskin; J Delwiche; D Duflot; N J Mason; S Vrønning-Hoffmann; G G B de Souza; A M Ferreira Rodrigues; F N Rodrigues; P Limão-Vieira
Journal:  Phys Chem Chem Phys       Date:  2012-01-09       Impact factor: 3.676

6.  Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

Authors:  M T Huizing; J B Vermorken; H Rosing; W W ten Bokkel Huinink; I Mandjes; H M Pinedo; J H Beijnen
Journal:  Ann Oncol       Date:  1995-09       Impact factor: 32.976

Review 7.  Potential Cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments.

Authors:  Paul Gougis; Marc Hilmi; Arthur Geraud; Olivier Mir; Christian Funck-Brentano
Journal:  Crit Rev Oncol Hematol       Date:  2021-04-27       Impact factor: 6.312

8.  Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.

Authors:  P L Crowell; S Lin; E Vedejs; M N Gould
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.

Authors:  V Kurowski; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  The use of complementary and alternative medicine among lymphoma and cancer patients with a solid tumor: Oncology clinics at Northern and Southern Turkey.

Authors:  Ayfer Bayindir Cevik; Ayse Cil Akinci; Sevgin Samancioglu Baglama
Journal:  Complement Ther Med       Date:  2019-08-12       Impact factor: 2.446

View more
  1 in total

1.  A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory.

Authors:  Dimple Kumari; Prabhat Ranjan; Tanmoy Chakraborty
Journal:  Struct Chem       Date:  2022-09-08       Impact factor: 1.795

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.